Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel

Aurelius Omlin, Oliver Sartor, Christian Rothermundt, Richard Cathomas, Johann S De Bono, Liji Shen, Zhen Su, Silke Gillessen

Research output: Contribution to journalArticlepeer-review

Abstract

INTRODUCTION: We hypothesized that the adverse event (AE) profile of cabazitaxel with regard to alopecia, nail changes, neuropathy, and dysgeusia differs from docetaxel.

MATERIALS AND METHODS: Prospectively collected data on treatment-emergent AEs (frequency and grade [G]) from clinical trial databases of docetaxel every 3 weeks (q3w) (in TAX327 and VENICE) and cabazitaxel q3w (in TROPIC) were analyzed.

RESULTS: The frequency of new or worsening AEs (all G and G3-4) for 1301 patients was significantly less for alopecia, nail changes, neuropathy, and dysgeusia for cabazitaxel compared with docetaxel.

CONCLUSION: Treatment with cabazitaxel might cause less alopecia, nail changes, neuropathy, and dysgeusia compared with docetaxel.

Original languageEnglish
Pages (from-to)e205-e208
JournalClinical Genitourinary Cancer
Volume13
Issue number4
DOIs
Publication statusPublished - Aug 2015

Keywords

  • Alopecia/epidemiology
  • Clinical Trials as Topic
  • Docetaxel
  • Drug-Related Side Effects and Adverse Reactions/epidemiology
  • Dysgeusia/epidemiology
  • Humans
  • Male
  • Nail Diseases/epidemiology
  • Peripheral Nervous System Diseases/epidemiology
  • Prospective Studies
  • Prostatic Neoplasms/drug therapy
  • Retrospective Studies
  • Taxoids/administration & dosage

Fingerprint

Dive into the research topics of 'Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel'. Together they form a unique fingerprint.

Cite this